Edinburgh Research Explorer

B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells

Research output: Contribution to journalArticle

Related Edinburgh Organisations

Open Access permissions

Open

Documents

http://jem.rupress.org/content/209/5/1001
Original languageEnglish
Pages (from-to)1001-1010
Number of pages10
JournalJournal of Experimental Medicine
Volume209
Issue number5
Early online date30 Apr 2012
DOIs
Publication statusPublished - 7 May 2012
EventEuropean Congress of Immunology - Glasgow
Duration: 5 Sep 20128 Sep 2012

Abstract

B cells have paradoxical roles in autoimmunity, exerting both pathogenic and protective effects. Pathogenesis may be antibody independent, as B cell depletion therapy (BCDT) leads to amelioration of disease irrespective of autoantibody ablation. However, the mecha- nisms of pathogenesis are poorly understood. We demonstrate that BCDT alleviates central nervous system autoimmunity through ablation of IL-6–secreting pathogenic B cells. B cells from mice with experimental autoimmune encephalomyelitis (EAE) secreted elevated levels of IL-6 compared with B cells from naive controls, and mice with a B cell–specific IL-6 deficiency showed less severe disease than mice with wild-type B cells. Moreover, BCDT ameliorated EAE only in mice with IL-6–sufficient B cells. This mechanism of pathogenesis may also operate in multiple sclerosis (MS) because B cells from MS patients produced more IL-6 than B cells from healthy controls, and this abnormality was normalized with
B cell reconstitution after Rituximab treatment. This suggests that BCDT improved disease progression, at least partly, by eliminating IL-6–producing B cells in MS patients. Taking these data together, we conclude that IL-6 secretion is a major mechanism of B cell–driven pathogenesis in T cell–mediated autoimmune disease such as EAE and MS.

Event

European Congress of Immunology

5/09/128/09/12

Glasgow

Event: Conference

Download statistics

No data available

ID: 3530457